{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:42:59Z","timestamp":1791571379679,"version":"4.3.4"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Obesity is associated with an increased risk of cancers, such as breast cancer. Roux-en-Y gastric bypass (RYGB) is a common surgical intervention used to induce weight loss, reduce comorbidities, and improve overall survival. Due to alterations in the gastrointestinal tract, RYGB is associated with changes in oral drug disposition, which can affect treatment outcomes. Oral antihormonal agents were monitored in 9 patients who previously underwent RYGB. The results of therapeutic drug monitoring and estradiol concentrations were analyzed, and a review of the relevant literature was performed. As only 1 of the 6 patients prescribed tamoxifen achieved a therapeutic endoxifen concentration with the standard dose of 20 mg\/d, a higher starting dose of 40 mg\/d was recommended to increase the probability of attaining a therapeutic plasma concentration. All patients with decreased CYP2D6 metabolic activity could not achieve therapeutic plasma concentrations; therefore, CYP2D6 genotyping was recommended before the initiation of tamoxifen therapy to identify patients who should be switched to aromatase inhibitors. Anastrozole and letrozole exposure in patients who underwent RYGB patients appeared sufficient, with no dose adjustment required. However, until more data become available, monitoring aromatase inhibitor efficacy is recommended. Monitoring the drug concentrations is a viable option; however, only indicative data on therapeutic drug monitoring are available. Therefore, estradiol concentrations should be measured.<\/jats:p>","DOI":"10.1097\/ftd.0000000000001159","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T13:05:06Z","timestamp":1701263106000},"page":"404-409","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Guidance for Dosing and Monitoring Oral Antihormonal Drugs in Patients with Breast Cancer After Roux-en-Y Gastric Bypass"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5115-3275","authenticated-orcid":false,"given":"Jurjen S.","family":"Kingma","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein\/Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W.L.","family":"Peeters","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherijne A.J.","family":"Knibbe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein\/Utrecht, the Netherlands;"},{"name":"Division of Systems Pharmacology & Pharmacy, Leiden Academic Center for Drug Research, Leiden University, Leiden, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette J.","family":"Agterof","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Antonius Hospital, Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.M.","family":"Derksen","sequence":"additional","affiliation":[{"name":"Department of Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e M.T.","family":"Burgers","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein\/Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel P.H.","family":"van den Broek","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein\/Utrecht, the Netherlands;"},{"name":"Department of Pharmaceutics, Faculty of Science, Utrecht University, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s11695-019-04099-6","article-title":"The impact of bariatric surgery on breast cancer recurrence: case series and review of literature","volume":"30","author":"Zhang","year":"2020","journal-title":"Obes Surg"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jama.296.2.193","article-title":"Adult weight change and risk of postmenopausal breast cancer","volume":"296","author":"Eliassen","year":"2006","journal-title":"JAMA"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjsurg.2021.03.016","article-title":"The effect of bariatric surgery on breast cancer incidence and characteristics: a meta-analysis and systematic review","volume":"222","author":"Lovrics","year":"2021","journal-title":"Am J Surg"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/joim.12012","article-title":"Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery","volume":"273","author":"Sj\u00f6str\u00f6m","year":"2013","journal-title":"J Intern Med"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2125.2012.04284.x","article-title":"Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes","volume":"74","author":"Darwich","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1111\/bcp.14913","article-title":"Oral drug dosing following bariatric surgery: general concepts and specific dosing advice","volume":"87","author":"Kingma","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40262-015-0259-1","article-title":"Altered drug disposition following bariatric surgery: a Research challenge","volume":"54","author":"Greenblatt","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/SLA.0b013e3181dbb572","article-title":"Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content","volume":"251","author":"Bell","year":"2010","journal-title":"Ann Surg"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.soard.2019.05.019","article-title":"CYP450 activities before and after Roux-en-Y gastric bypass: correlation with their intestinal and liver content","volume":"15","author":"Lloret-Linares","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1007\/s11095-015-1752-9","article-title":"The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery","volume":"32","author":"Brill","year":"2015","journal-title":"Pharm Res"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1176\/appi.ajp.2011.11050719","article-title":"The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors","volume":"169","author":"Hamad","year":"2012","journal-title":"Am J Psychiatry"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.soard.2021.12.023","article-title":"The APB study: apixaban pharmacokinetics in bariatric patients before to 1 year after vertical sleeve gastrectomy or Roux-en-Y gastric bypass","volume":"18","author":"Steele","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","article-title":"Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes","volume":"89","author":"Madlensky","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cpt.1007","article-title":"Clinical Pharmacogenetics implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy","volume":"103","author":"Goetz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.steroids.2014.08.007","article-title":"Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole","volume":"99","author":"Ingle","year":"2015","journal-title":"Steroids"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/clpt.2011.174","article-title":"Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age","volume":"90","author":"Desta","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40262-018-0683-0","article-title":"Therapeutic drug monitoring of oral anti-hormonal drugs in oncology","volume":"58","author":"Groenland","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1158\/0008-5472.CAN-09-3024","article-title":"Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer","volume":"70","author":"Ingle","year":"2010","journal-title":"Cancer Res"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40262-021-01077-z","article-title":"Therapeutic drug monitoring of endoxifen for tamoxifen precision dosing: feasible in patients with hormone-sensitive breast cancer","volume":"61","author":"Braal","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1592\/phco.30.2.217","article-title":"Tamoxifen malabsorption after roux-en-Y gastric bypass surgery: case series and review of the literature","volume":"30","author":"Wills","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s002280100359","article-title":"The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers","volume":"57","author":"Tamminga","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.xfre.2021.04.009","article-title":"Secondary azoospermia after sleeve gastrectomy: a case report","volume":"2","author":"Gomez","year":"2021","journal-title":"F&S Rep"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.18.00307","article-title":"Tamoxifen Pharmacogenetics and metabolism: results from the prospective CYPTAM study","volume":"37","author":"Sanchez-Spitman","year":"2019","journal-title":"J Clin Oncol"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.breast.2014.02.008","article-title":"Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype","volume":"23","author":"Martinez de Due\u00f1as","year":"2014","journal-title":"Breast"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-020-0166-y","article-title":"Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study","volume":"6","author":"Elliott","year":"2020","journal-title":"NPJ breast cancer"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3332\/ecancer.2018.821","article-title":"Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer","volume":"12","author":"Zekri","year":"2018","journal-title":"Ecancermedicalscience"},{"issue":"suppl 2","key":"R29-20250603","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.breast.2013.07.008","article-title":"Obesity and endocrine therapy: host factors and breast cancer outcome","volume":"22","author":"Goodwin","year":"2013","journal-title":"Breast"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s12282-020-01213-w","article-title":"Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review","volume":"28","author":"Shirdarreh","year":"2021","journal-title":"Breast Cancer"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00432-013-1557-3","article-title":"Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole","volume":"140","author":"Kyvernitakis","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2012.46.2622","article-title":"Need for estradiol assays with a lower functional sensitivity in clinical studies examining postmenopausal women treated with aromatase inhibitors","volume":"31","author":"Pauwels","year":"2013","journal-title":"J Clin Oncol"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.2012.42.0273","article-title":"Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer","volume":"30","author":"Folkerd","year":"2012","journal-title":"J Clin Oncol"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1007\/s11695-019-04112-y","article-title":"Nutrition, physical activity, and prescription of supplements in pre- and post-bariatric surgery patients: a practical guideline","volume":"29","author":"Tabesh","year":"2019","journal-title":"Obes Surg"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:13:36Z","timestamp":1748970816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001159","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"2023-08-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}